IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merial Limited v Novartis AG [2013] APO 65
Patent Application: 2010206029
Title:Palatable ductile chewable veterinary composition
Patent Applicant: Novartis AG
Opponent: Merial Limited
Hearing Officer: P M Spann, Deputy Commissioner of Patents
Decision Date: 5 December 2013
Hearing Date: 25 November 2013
Catchwords: PATENTS – extension of time to file evidence in answer – reg 5.9 – whether applicant has acted promptly and diligently at all times – whether circumstances beyond control – extension refused.
Representation: Patent applicant: M Caine, Davies Collison Cave
Opponent:M Caulfield, FB Rice
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2010206029
Title:Palatable ductile chewable veterinary composition
Patent Applicant: Novartis AG
Opponent: Merial Limited
Date of Decision: 5 December 2013
DECISION
Extension of time refused.
REASONS FOR DECISION
This matter concerns a request for an extension of time to file evidence in answer and is determined under regulation 5.9 of the Patents Regulations as amended on 15 April 2013 by the Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1).
Background
Patent application 2010206029 was filed by Novartis AG (Novartis) on 29 July 2010 as a divisional of 2008201605. The parent application was itself a divisional application. It was accepted and opposed but was withdrawn on 2 April 2013 after evidence in support of that opposition was filed.
The present application was advertised as accepted on 9 August 2012 and a notice of opposition to the grant of a patent was filed in the name of Merial Limited (Merial) on 29 November 2012. A statement of grounds and particulars was served and filed on 31 January 2013 and the evidence in support completed on 27 April 2013.
Consequently, the period for filing evidence in answer commenced on 27 April 2013 (the Commissioner’s letter in this regard is in error). However due to the operation of subregulation 23.26(2)(Item 4), the end of the period for filing evidence support became 29 July 2013.
On 18 July 2013 the attorney for Novartis filed the first declaration made by its expert Dr James Rowe as part evidence in answer. It then filed on 29 July 2013 a request for an extension of time of three months to 29 October 2013. The reasons provided were essentially that, while significant progress had been made, Dr Rowe had gone on holiday for an extended period before the evidence could be completed.
The extension was not objected to and a delegate of the Commissioner granted the extension on 14 August 2013 for the period requested. On 24 October 2013 Novartis filed Dr Rowe’s 2nd, 3rd and 4th declarations as part evidence in answer. Then on 29 October 2013 Novartis filed the present request for an extension of time for an additional period of two months to 29 December 2013. A delegate on 1 November 2013 informed the parties that, subject to a party requesting to be heard, the Commissioner intended to grant the extension.
Merial notified the Commissioner on 7 November 2013 that…
Keep reading for free
Create a free CaseChat account to read Merial Limited v Novartis AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] APO 65
- Decision Date
CaseChat Overview and Summary
The decision of the court was that the extension of time sought by Novartis was refused. The court found that Novartis had not acted promptly and diligently in the preparation of its evidence in answer and that there were not exceptional circumstances that warranted the extension. The court directed that the period for filing evidence in reply commences from the date of this decision. The court also directed that the declarations filed on 18 and 27 November are not evidence in answer in relation to the opposition. Novartis may make an application for leave to file the declarations as further evidence under subregulation 5.10(4) as it existed before 15 April 2013. The court made no comment on the prospects of success for such an application other than that it will be considered on its merits. Otherwise, the declarations may be information that the Commissioner takes into account under regulation 5.11 as it existed before 15 April 2013. The court awarded costs in accordance with Schedule 8 of the Patents Regulations against the patent applicant Novartis.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.